World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
61212
World Ranking
8115
National Ranking
112

Jean-Yves Douillard publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jean-Yves Douillard sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 501 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jean-Yves Douillard D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jean-Yves Douillard sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jean-Yves Douillard is affiliated with the European Society for Medical Oncology in Switzerland. The primary field of study for their research is medicine, with a focus on oncology, pulmonary and respiratory medicine, economics and econometrics, public health, environmental and occupational health, and radiology, nuclear medicine and imaging.

The scientist's work covers several topics including:

  • Lung cancer diagnosis and treatment
  • Health systems, economic evaluations, quality of life
  • COVID-19 and healthcare impacts
  • Economic and financial impacts of cancer
  • Lung cancer treatments and mutations
  • Gastric cancer management and outcomes
  • Global cancer incidence and screening

Jean-Yves Douillard has contributed to various research papers, among which are:

  • "Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus" (2020), published in Annals of Oncology
  • "Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)" (2021), published in ESMO Open
  • "Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS" (2020), published in Annals of Oncology
  • "Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer" (2020), published in Annals of Oncology
  • "ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer" (2020), published in ESMO Open

The frequent co-authors associated with Jean-Yves Douillard's research include:

  • George Pentheroudakis
  • Solange Peters
  • Giuseppe Curigliano
  • Josep Tabernero
  • Andrés Cervantes

The scientist's research has been published mainly in the following venues:

  • ESMO Open
  • Annals of Oncology
  • JNCI Journal of the National Cancer Institute
  • JCO Global Oncology
  • Clinical Cancer Research

Best Publications

  • Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

    J Y Douillard;D Cunningham;Arnaud Roth;M Navarro

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Jean Pierre Pignon;Hélène Tribodet;Giorgio V. Scagliotti;Jean Yves Douillard

  • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

    Jean Yves Douillard;Kelly S. Oliner;Salvatore Siena;Josep Tabernero

  • Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]) : a randomised controlled trial

    Jean Yves Douillard;Rafael Rosell;Mario De Lena;Francesco Carpagnano

  • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

    Edward S. Kim;Vera Hirsh;Tony Mok;Mark A. Socinski

  • Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

    Jean Yves Douillard;Salvatore Siena;James Cassidy;Josep Tabernero

  • Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

    Ghassan K. Abou-Alfa;Lawrence Schwartz;Sergio Ricci;Dino Amadori

  • Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

    T Le Chevalier;D Brisgand;J Y Douillard;J L Pujol

  • Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

    Sylvie Negrier;Bernard Escudier;Christine Lasset;Jean-Yves Douillard

  • Radiotherapy Alone Versus Combined Chemotherapy and Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a Randomized Trial in 353 Patients

    T Le Chevalier;R Arriagada;E Quoix;P Ruffie

  • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

    Martin Reck;Rolf Kaiser;Anders Mellemgaard;Jean-Yves Douillard

  • Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.

    F. Mosele;J. Remon;J. Mateo;C. B. Westphalen

  • Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

    D. Arnold;B. Lueza;J.-Y. Douillard;M. Peeters

  • ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

    C. Luchini;F. Bibeau;M.J.L. Ligtenberg;N. Singh

  • Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

    Jean Yves Douillard;Frances A. Shepherd;Vera Hirsh;Tony Mok

  • Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

    Jean Yves Douillard;S. Siena;J. Cassidy;J. Tabernero

  • Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients

    C. Louvet;T. André;J.M. Tigaud;E. Gamelin

  • ESMO-Magnitude of Clinical Benefit Scale version 1.1

    N.I. Cherny;U. Dafni;J. Bogaerts;N.J. Latino

Frequent Co-Authors

Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Silvia Novello
Silvia Novello University of Turin
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Salvatore Siena
Salvatore Siena University of Milan
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Lesley Seymour
Lesley Seymour Queen's University
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Marc Peeters
Marc Peeters University of Antwerp
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While studying Medicine in the USA typically means pursuing a traditional MD or DO, there are many alternative online degrees and career pathways that can complement or expand your expertise in healthcare. For those interested in healthcare administration, a cahme accredited online mha programs list helps future leaders find reputable programs that meet industry standards for quality.

Nursing professionals might consider advancing their careers with a Bachelor of Science in Nursing. Some rn bsn online programs no clinicals allow registered nurses to complete their bachelor’s degree entirely online, with no clinical requirements—ideal for working nurses needing flexibility.

For nurses seeking the highest clinical leadership roles, accelerated dnp programs enable faster paths to a Doctor of Nursing Practice. Additionally, students can explore dnp programs designed for streamlined, efficient study, making advanced nursing education more accessible than ever.

Best Scientists Citing Jean-Yves Douillard

Trending Scientists

Recently Published Articles